Cupertino, CA, United States of America

Thomas J Graddis

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2001-2006

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Thomas J Graddis: Innovator in Hematopoietic Growth Factor Research

Introduction

Thomas J Graddis is a notable inventor based in Cupertino, CA (US). He has made significant contributions to the field of hematopoietic growth factors, particularly through his innovative research and patented methods.

Latest Patents

Graddis holds 2 patents that focus on methods of using mutant flt3-ligand polypeptides to induce cellular expansion. His latest patents include a screening method for identifying mutant polypeptides that have at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction. This method also discloses mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this technique, along with nucleic acids encoding these flt3-L mutant polypeptides. Furthermore, the patents detail methods of treatment involving both in vitro and in vivo use of the mutant polypeptides and nucleic acids.

Career Highlights

Graddis is currently associated with Immunex Corporation, where he continues to advance his research in the field. His work has been instrumental in developing new therapeutic approaches that leverage the unique properties of flt3-L mutants.

Collaborations

One of his notable collaborators is Jeffrey T McGrew, with whom he has worked closely on various projects related to his patents.

Conclusion

Thomas J Graddis is a prominent figure in the field of hematopoietic growth factors, with a focus on innovative methods that have the potential to transform treatment approaches. His contributions through patents and research continue to impact the scientific community significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…